Show simple item record

dc.contributor.authorFaivre, S
dc.contributor.authorNiccoli, P
dc.contributor.authorCastellano, D
dc.contributor.authorValle, Juan W
dc.contributor.authorHammel, P
dc.contributor.authorRaoul, J
dc.contributor.authorVinik, A
dc.contributor.authorVan Cutsem, E
dc.contributor.authorBang, Y
dc.contributor.authorLee, S
dc.contributor.authorBorbath, I
dc.contributor.authorLombard-Bohas, C
dc.contributor.authorMetrakos, P
dc.contributor.authorSmith, D
dc.contributor.authorChen, J
dc.contributor.authorRuszniewski, P
dc.contributor.authorSeitz, J
dc.contributor.authorPatyna, S
dc.contributor.authorLu, D
dc.contributor.authorIshak, K
dc.contributor.authorRaymond, E
dc.date.accessioned2017-01-31T16:15:17Z
dc.date.available2017-01-31T16:15:17Z
dc.date.issued2016-11-10
dc.identifier.citationSunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. 2016, Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid27836885
dc.identifier.doi10.1093/annonc/mdw561
dc.identifier.urihttp://hdl.handle.net/10541/620110
dc.description.abstractIn a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.titleSunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.en
dc.typeArticleen
dc.contributor.departmentMedical Oncology and Gastroenterology Department, Service Inter-Hospitalier de Cancerologie, Hopital Beaujon, Clichy, Franceen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractIn a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.


This item appears in the following Collection(s)

Show simple item record